<DOC>
	<DOCNO>NCT01205685</DOCNO>
	<brief_summary>Erlotinib attack part cancer cell help live grow . Studies do human being show drug make difference way anti-estrogens work hormone-sensitive breast cancer . OSI-906 attack different part cancer cell help live grow . Studies do laboratory show OSI-906 make difference way anti-estrogens work hormone-sensitive breast cancer .</brief_summary>
	<brief_title>Endocrine Therapy + OSI-906 With Without Erlotinib Hormone-Sensitive Metastatic Breast Cancer</brief_title>
	<detailed_description>The safety run component trial determine safety profile OSI-906 , erlotinib anti-endocrine treatment combination . The phase II component evaluate antitumor activity combination OSI-906 , erlotinib endocrine therapy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<criteria>Patients must provide informed write consent . Patients must ≥18 year age . ECOG performance status 01 . Patients clinical stage IV invasive mammary carcinoma , previously document histological analysis , ERpositive and/or PRpositive immunohistochemistry ( IHC ) , previous endocrine therapy metastatic setting metastatic recurrence within 6 month adjuvant endocrine therapy . Patients may either measurable nonmeasurable disease , allow . Patients whose breast cancer also HER2overexpressed ( IHC 3+ FISHpositive ) need previous treatment exposure trastuzumab ( Herceptin® ) Life expectancy ≥ 6 month Patients must adequate hematologic , hepatic , renal function . All test must obtain less 2 week study entry . This include : ANC ≥1250/mm3 Platelet count ≥100,000/mm3 Creatinine ≤1.5X upper limit normal Bilirubin , SGOT , SGPT ≤ 1.5 X upper limit normal liver metastasis present* Bilirubin , SGOT , SGPT , alkaline phosphatase ≤ 3 X upper limit normal liver metastasis present* *for patient Gilbert 's syndrome , direct bilirubin measure instead total bilirubin Able swallow retain oral medication . Premenopausal patient must negative pregnancy test prior participate study . Women childbearing age male counter part use barrier method contraception 3 month follow protocol therapy . Postmenopausal female subject define prior protocol enrollment follow : Subjects least 55 year age ; Subjects 55 year age amenorrheic least 12 month folliclestimulating hormone ( FSH ) value ≥40 IU/L estradiol level ≤20 IU/L ; Prior bilateral oophorectomy prior radiation castration amenorrhea least 6 month . Patients may receive concurrent radiation therapy painful bone metastasis area impend bone fracture long radiation therapy initiate prior study entry . Patients receive prior radiotherapy must recover toxicity induce treatment ( toxicity grade ≤ 1 ) . Patients must diseasefree prior invasive cancer &gt; 5 year exception basal squamous cancer skin cervical carcinoma situ . Subjects must complete screen assessment outline protocol . Patients must available tissue ( archive formalinfixed paraffin embed block ( FFPB ) fresh frozen tissue original diagnosis metastatic setting ) correlative study . Tissue need sent VUMC ( see Appendix E ) time registration . Patients able start study drug without tissue availability . Locally recurrent resectable breast cancer . Pregnant lactating woman . Patients must &gt; 4 prior chemotherapy treatment metastatic setting . This restriction include endocrine therapy single agent biologic therapy . Use CYP3A4 CYP1A2 modifier drug prolong QTcF high risk Torsade de Pointes ( see Appendix A ) Any kind malabsorption syndrome significantly affect gastrointestinal function . History malignancy within 5 year prior enrollment . Subjects history completely resect nonmelanoma skin cancer successfully treat situ carcinoma eligible . Patients baseline QTcF &gt; 450 msec Patients diabetes , glucose &gt; 160 mg/dL receive ongoing antihyperglycemic therapy Uncontrolled intercurrent illness include , limited : ongoing active infection require parenteral antibiotic impairment lung function ( COPD &gt; grade 2 , lung condition require oxygen therapy ) symptomatic congestive heart failure ( class III IV New York Heart Association classification heart disease ) unstable angina pectoris , angioplasty , stenting , myocardial infarction within 6 month uncontrolled hypertension ( systolic blood pressure &gt; 180 mm Hg diastolic blood pressure &gt; 100 mm Hg , find two consecutive measurement separate 1week period despite adequate medical support ) clinically significant cardiac arrhythmia ( multifocal premature ventricular contraction , bigeminy , trigeminy , ventricular tachycardia symptomatic require treatment [ National Cancer Institute Common Terminology Criteria Adverse Events , Version 4.0 , grade 3 ] psychiatric illness/social situation would compromise patient safety limit compliance study requirement include maintenance compliance/pill diary Patients symptomatic brain metastasis ( patient history brain metastasis must clinically stable 3 week completion radiation treatment take steroid therapeutic anticonvulsant CYP3A4 modifier ) Patients asymptomatic brain metastasis prophylactic anticonvulsant CYP3A4 modifier Concurrent anticancer therapy ( chemotherapy , radiation therapy , surgery , immunotherapy , hormonal therapy , biologic therapy ) one specify protocol . Patients must discontinue cancer therapy 1 week prior first dose study medication , well recover toxicity ( ≤ grade 1 , except alopecia , neuropathy , ANC , ≥ 1250/mm3 ) induce previous treatment . Any investigational drug discontinue 2 week prior first dose study medication . Prior therapy IGF1R inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>